文献速递淋巴瘤造血干细胞移植与细胞治疗

OUTREACH:lisocabtagene maraleucel 在社区站点作为门诊或住院治疗复发/难治性大B细胞淋巴瘤的2期研究

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
PubMed 文献 · Blood Adv · 2024-01-01

OUTREACH 是在美国社区站点开展的2期研究,评估复发/难治性大B细胞淋巴瘤患者接受 lisocabtagene maraleucel 后门诊监测的安全性和疗效。82例患者中70%门诊监测、30%住院监测;门诊与住院患者≥3级细胞因子释放综合征均为0%,神经事件分别为12%和4%,感染分别为12%和8%,持续血细胞减少分别为33%和32%。客观缓解率80%,完全缓解率54%,中位缓解持续时间14.75个月(95%CI 5.0至未达到)。

要点

  • 门诊监测患者中25%输注后从未住院,32%在输注当天起72小时内住院。
  • 门诊与住院患者≥3级细胞因子释放综合征均为0%,神经事件分别为12%和4%。
  • 客观缓解率80%,完全缓解率54%,中位缓解持续时间14.75个月。

核心结论

  • lisocabtagene maraleucel 在复发/难治性大B细胞淋巴瘤患者中显示出有意义的疗效和良好的安全性。
  • 数据支持在社区站点进行 lisocabtagene maraleucel 给药并配合门诊监测的可行性。

研究设计与样本

  • OUTREACH 为2期研究,在美国社区站点评估 lisocabtagene maraleucel 治疗后门诊监测的安全性和疗效。
  • 纳入接受过≥2线治疗的复发/难治性大B细胞淋巴瘤成人患者,接受 lisocabtagene maraleucel 治疗。
  • 门诊或住院监测由研究者酌情决定;主要终点为≥3级细胞因子释放综合征、神经事件、持续血细胞减少和感染的发生率,疗效为次要终点。
  • 82例患者接受 lisocabtagene maraleucel,其中门诊监测70%、住院监测30%;中位随访10.6个月(范围1.0-24.5)。

主要发现

  • 门诊与住院患者≥3级细胞因子释放综合征发生率分别为0%和0%,神经事件分别为12%和4%,感染分别为12%和8%,持续血细胞减少分别为33%和32%。
  • 门诊监测患者中25%输注后从未住院,32%在输注当天起72小时内住院;至住院的中位时间为5.0天(范围2-310)。
  • lisocabtagene maraleucel 治疗后门诊患者中位初始住院时长为6.0天(范围1-28),住院患者为15.0天(范围3-31)。
  • 客观缓解率为80%,完全缓解率为54%,中位缓解持续时间为14.75个月(95%CI 5.0至未达到)。

临床怎么用

  • 原文结论认为 lisocabtagene maraleucel 在复发/难治性大B细胞淋巴瘤患者中显示出有意义的疗效和良好的安全性。
  • 原文结论指出数据支持在社区站点进行 lisocabtagene maraleucel 给药并配合门诊监测的可行性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB chimeric antigen receptor (CAR) T-cell product approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We present the OUTREACH primary analysis, evaluating the safety and efficacy of outpatient monitoring after liso-cel treatment at community sites in the United States. Adults with R/R LBCL after ≥2 prior lines of therapy received liso-cel. Outpatient vs inpatient monitoring was per investigator discretion. The primary end points were incidences of grade ≥3 cytokine release syndrome (CRS), neurological events (NEs), prolonged cytopenia, and infections. Efficacy was a secondary end point. Eighty-two patients received liso-cel (outpatient monitored, 70%; inpatient monitored, 30%). The median follow-up was 10.6 months (range, 1.0-24.5). In outpatients and inpatients, grade ≥3 CRS occurred in 0% and 0%, NEs in 12% and 4%, infections in 12% and 8%, and prolonged cytopenia in 33% and 32%, respectively. Among outpatients, 25% were never hospitalized after infusion, and 32% were hospitalized ≤72 hours after the day of infusion; the median time to hospitalization was 5.0 days (range, 2-310). The median initial hospitalization duration after liso-cel was 6.0 days (range, 1-28) for outpatients and 15.0 days (range, 3-31) for inpatients. Objective response rate was 80%, complete response rate was 54%, and the median duration of response was 14.75 months (95% confidence interval, 5.0 to not reached). OUTREACH is, to our knowledge, the first and largest study to prospectively assess CAR T-cell therapy with outpatient monitoring in community-based medical centers. Liso-cel demonstrated meaningful efficacy with favorable safety in patients with R/R LBCL. Data support the feasibility of liso-cel administration at community sites with outpatient monitoring. This trial was registered at www.ClinicalTrials.gov as #NCT03744676.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Linhares Y, Freytes CO, Cherry M, et al. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL. Blood Adv. 2024. PMID: 39347584. doi:10.1182/bloodadvances.2024013254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。